Loading...
•
Dec 27, 2025
Haemonetics Q3 2026 Earnings Report
Haemonetics reported a decrease in revenue but an increase in net income and adjusted earnings per diluted share for the third quarter of fiscal 2026.
Key Takeaways
Haemonetics reported third quarter fiscal 2026 revenue of $339.0 million, a 2.7% decrease compared to the prior year. Despite the revenue decline, net income increased by 19.3% to $44.7 million, and adjusted earnings per diluted share rose by 10.1% to $1.31. The company also saw strong cash flow from operating activities, up 113.8% to $93.6 million.
Third quarter fiscal 2026 revenue was $339.0 million, down 2.7% from the prior year.
Net income for the quarter increased by 19.3% to $44.7 million, with diluted EPS of $0.95.
Adjusted earnings per diluted share grew by 10.1% to $1.31.
Cash flow from operating activities significantly increased by 113.8% to $93.6 million.
Revenue by Segment
Forward Guidance
Haemonetics updated its fiscal 2026 GAAP revenue and organic revenue growth guidance, and raised its adjusted operating margin, adjusted earnings per diluted share, and free cash flow guidance.
Positive Outlook
- Total Company Organic, ex-CSL revenue growth guidance raised to 8-10% from 7-10%.
- Adjusted operating margin guidance maintained at 26-27%.
- Adjusted earnings per diluted share guidance raised to $4.90-$5.00 from $4.80-$5.00.
- Free cash flow guidance raised to $200M-$220M from $170M-$210M.
- Free cash flow to adjusted net income guidance raised to >80% from >70%.
Challenges Ahead
- Total Company Reported revenue guidance maintained at (1-3)%.
- Total Company Organic revenue guidance maintained at 0-2%.
- Blood Center Reported revenue guidance maintained at (16-18)%.
- Blood Center Organic revenue guidance maintained at 1-3%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...